WO2018107364A1 - Collinsella shenzhenensis et ses applications - Google Patents

Collinsella shenzhenensis et ses applications Download PDF

Info

Publication number
WO2018107364A1
WO2018107364A1 PCT/CN2016/109689 CN2016109689W WO2018107364A1 WO 2018107364 A1 WO2018107364 A1 WO 2018107364A1 CN 2016109689 W CN2016109689 W CN 2016109689W WO 2018107364 A1 WO2018107364 A1 WO 2018107364A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
collins
group
collinsella
mammal
Prior art date
Application number
PCT/CN2016/109689
Other languages
English (en)
Chinese (zh)
Inventor
邹远强
薛文斌
肖亮
李晓平
余靖宏
刘传
Original Assignee
深圳华大基因研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳华大基因研究院 filed Critical 深圳华大基因研究院
Priority to PCT/CN2016/109689 priority Critical patent/WO2018107364A1/fr
Priority to CN201680091522.4A priority patent/CN110049772A/zh
Publication of WO2018107364A1 publication Critical patent/WO2018107364A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • Another object of the present invention is to provide a method of lowering blood lipids, controlling a decrease in body weight of a mammal, and/or reducing a disease activity index (DAI) of a mammal, and uses thereof.
  • DAI disease activity index
  • the Collinella is Collinsella shenzhenensis TF06-26, and the accession number is GDMCC NO.: 60090.
  • a second aspect of the invention provides a composition comprising: (a) a safe and effective amount of Collins and/or a metabolite thereof according to the first aspect of the invention; and (b) food acceptable A carrier or a pharmaceutically acceptable carrier.
  • the liquid formulation is selected from the group consisting of a solution preparation or a suspension product.
  • the method further comprises the step of mixing with a probiotic, and/or a prebiotic.
  • the terms “Collinia”, “Shenzhen Collins”, “Collinsella shenzhenensis”, “Shenzhen Collins of the present invention”, “Clinicus of the present invention” may mutually Change to use.
  • the strain is Collinsella shenzhenensis TF06-26, deposited under the number GDMCC NO.: 60090, isolated from the feces of a human (preferably, healthy female), in particular, isolated from the intestines of adolescent females. .
  • the microecological preparation comprises (a) a safe and effective amount of Collins from Shenzhen and/or its metabolites; and (b) a food acceptable carrier or a pharmaceutically acceptable carrier.
  • the formulation further comprises a growth factor (such as milk growth factor, preferably including a vitamin, an anthraquinone, and/or a pyrimidine).
  • Collins from Shenzhen can be obtained by conventional methods.
  • the method comprises ingesting a pharmaceutical composition, a food composition, a beverage composition, or a combination thereof of the present invention.
  • the subject includes mammals such as humans.
  • TF06-26 was cultured to logarithmic growth phase, and the TF06-26 bacterial solution was applied to the plate (PYG medium). After application, the antibiotic drug-sensitive tablets were applied. Then, it was placed under anaerobic conditions at 37 ° C for 48 h. The diameter of the zone of inhibition was measured, and the results are shown in Table 2.
  • a certain amount of cholesterol was weighed and dissolved in ethanol at a concentration of 10 mg/mL, and sterilized by filtration. Add the prepared PYG medium to 10 mg/mL bile salt (autoclave), 10% mass concentration of sodium thioglycolate (filter sterilization) and cholesterol, mix well, and then wait for 3% of the inoculum.
  • the test strain was inoculated into the medium, wherein the strain to be tested was TF06-26, and another commercial cholesterol-lowering probiotic, Lactobacillus plantarum Lp299v (purchased from Probi, Sweden), and the two bacteria were separately compared.
  • the inoculum was cultured under anaerobic conditions at 37 ° C for 72 h.
  • Table 7 and Figure 5 show that the length of the colon of the TF06-26 group was significantly longer than that of the model group (*P value ⁇ 0.05), while the length of the colon of the TF06-26 group was longer than the positive drug VSL # 3 group. The long, indicating that TF06-26 is better than VSL # 3 for disease improvement in UC mice. Thus, TF06-26 can significantly slow the lesions in the colon of mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des applications de Collinsella shenzhenensis dans le traitement et/ou la prévention de maladies associées à l'inflammation et de maladies cardiovasculaires. L'invention concerne également une composition utilisée pour traiter et/ou prévenir les maladies liées à l'inflammation et les maladies cardiovasculaires, comprenant des médicaments, des boissons, des aliments ou des compositions d'aliments pour animaux, et un procédé pour soulager les maladies du tractus intestinal des mammifères, diminuer la graisse sanguine des mammifères, réguler la réduction du poids des mammifères et/ou diminuer les indices d'activité de maladie des mammifères.
PCT/CN2016/109689 2016-12-13 2016-12-13 Collinsella shenzhenensis et ses applications WO2018107364A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/109689 WO2018107364A1 (fr) 2016-12-13 2016-12-13 Collinsella shenzhenensis et ses applications
CN201680091522.4A CN110049772A (zh) 2016-12-13 2016-12-13 深圳柯林斯菌(Collinsella shenzhenensis)及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/109689 WO2018107364A1 (fr) 2016-12-13 2016-12-13 Collinsella shenzhenensis et ses applications

Publications (1)

Publication Number Publication Date
WO2018107364A1 true WO2018107364A1 (fr) 2018-06-21

Family

ID=62557827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/109689 WO2018107364A1 (fr) 2016-12-13 2016-12-13 Collinsella shenzhenensis et ses applications

Country Status (2)

Country Link
CN (1) CN110049772A (fr)
WO (1) WO2018107364A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112899360A (zh) * 2021-02-02 2021-06-04 北京航空航天大学 一种检测特雷彻·柯林斯综合征发生概率的组合物的应用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006314219A (ja) * 2005-05-11 2006-11-24 Asahi Breweries Ltd 腸内細菌を利用した胆汁酸の吸着方法、および胆汁酸吸着物質
WO2010125421A1 (fr) * 2009-04-30 2010-11-04 Compagnie Gervais Danone Utilisation de collinsella aerofaciens pour réduire les ballonnements
WO2012142605A1 (fr) * 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
CN104413334A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
EP2995314A1 (fr) * 2014-09-12 2016-03-16 Swecure AB Utilisation de collinsella pour le traitement de la maladie inflammatoire de l'intestin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006314219A (ja) * 2005-05-11 2006-11-24 Asahi Breweries Ltd 腸内細菌を利用した胆汁酸の吸着方法、および胆汁酸吸着物質
WO2010125421A1 (fr) * 2009-04-30 2010-11-04 Compagnie Gervais Danone Utilisation de collinsella aerofaciens pour réduire les ballonnements
WO2012142605A1 (fr) * 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
CN104413334A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
EP2995314A1 (fr) * 2014-09-12 2016-03-16 Swecure AB Utilisation de collinsella pour le traitement de la maladie inflammatoire de l'intestin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TANNOCK, G. W. ET AL.: "The Bowel Microbiota and Inflammatory Bowel Diseases. The Bo-welMicrobiota and Inflammatory Bowel Diseases", INTERNATIONAL JOURNAL OF INFLAMMATION, vol. 2010, 31 December 2010 (2010-12-31), pages 1 - 9 *
WENG, XINGBEI ET AL.: "Human Intestinal Microbiota and Diseases", CHINESE JOURNAL OF MICROECOLOGY, vol. 23, no. 7, 31 July 2011 (2011-07-31), pages 662 - 666 and 669 *
XIONG, JIANHUI ET AL.: "The Relationship of Veillonella spp and C. Coccoides Subgroup Levels in Gut Microbiota with Type 2 Diabetes Mellitus in Uygurs and Kazaks of Xinjiang", CHINESE JOURNAL OF MICROECOLOGY, vol. 27, no. 6, 30 June 2015 (2015-06-30), pages 633 - 637 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112899360A (zh) * 2021-02-02 2021-06-04 北京航空航天大学 一种检测特雷彻·柯林斯综合征发生概率的组合物的应用方法

Also Published As

Publication number Publication date
CN110049772A (zh) 2019-07-23

Similar Documents

Publication Publication Date Title
US10806759B2 (en) Christensenella intestinihominis and application thereof
CN111280252B (zh) 长双歧杆菌长亚种、含其的组合物及用途
WO2019227418A1 (fr) Composition et ses applications
WO2018112739A1 (fr) Bifidobacterium pseudocatenulatum, son procédé de culture et application coorespondante
WO2018112741A1 (fr) Lactobacillus acidophilus, sa méthode de culture et son application
JP6990303B2 (ja) Ｍｅｇａｍｏｎａｓ ｆｕｎｉｆｏｒｍｉｓ及びその適用
CN106479906B (zh) 肠道细菌丁酸杆菌(Butyribacter intestini)及其应用
WO2018112740A1 (fr) Lactobacillus gasseri, procédé de culture et application de ce dernier
CN111281894B (zh) 加氏乳杆菌在预防和/或治疗代谢性疾病中的用途和组合物
CN112888448B (zh) 单形巨单胞菌在预防和/或治疗代谢性疾病中的用途
CN111093682B (zh) 丁酸杆菌(Butyribacter intestini)在预防和/或治疗炎症相关疾病的应用
CN117645955A (zh) 具有促进肠上皮细胞恢复作用的直肠真杆菌及其应用
US10799540B2 (en) Faecalibacterium longum and application thereof
WO2019227414A1 (fr) Composition et ses applications
WO2019051789A1 (fr) Anaerofustis stercorihominis et ses applications
WO2018107364A1 (fr) Collinsella shenzhenensis et ses applications
CN110062806B (zh) 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
WO2019227417A1 (fr) Composition et ses applications
CN112867500B (zh) 人粪厌氧棒形菌在预防和/或治疗代谢性疾病中的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16923853

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16923853

Country of ref document: EP

Kind code of ref document: A1